Physician profile
Glen Henry
NPI 1720077324
$5,174.70
in general payments reported to CMS, 2019-2025
20 companies · $1,348 in 2025
The $1,348 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $125 · 2021: $176 · 2022: $1,097 · 2023: $875 · 2024: $774 · 2025: $1,348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,996.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $933.66 | 2019-2025 | Impella |
| Shockwave Medical, INC | $742.82 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Boston Scientific Corporation | $736.28 | 2019-2025 | General - Balloon Catheters, General - Vascular Access, Rotapro |
| Asahi Intecc USA, INC. | $626.85 | 2019-2025 | Asahi Peripheral Vascular Wires |
| Philips North America LLC | $389.05 | 2022 | |
| Abbott Laboratories | $309.93 | 2019-2022 | |
| Medtronic, INC. | $293.68 | 2022-2024 | Onyx Frontier |
| Terumo Medical Corporation | $228.38 | 2022-2023 | |
| Biotronik INC. | $186.89 | 2024-2025 | Orsiro Mission, Nhancer Rx, Recross |
| Inari Medical, INC. | $118.97 | 2022-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cardiovascular Systems INC. | $115.77 | 2021 | |
| Medtronic Vascular, INC. | $91.33 | 2019 | |
| Teleflex LLC | $90.97 | 2025 | Orsiro Mission, Trapliner |
| Amgen INC. | $84.85 | 2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.39 | 2024-2025 | Lifevest |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $63.05 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $41.40 | 2023-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $20.61 | 2023 | |
| Merit Medical Systems INC | $19.82 | 2025 | Prelude Introducers |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glen Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.